Processa Pharmaceuticals Inc (PCSA) has a current Price-to-Book (P/B) ratio of 1.06. Compared to its 3-year average P/B ratio of 1.09, the current P/B ratio is approximately -2.90% higher. Relative to its 5-year average P/B ratio of 1.85, the current P/B ratio is about -42.45% higher. Processa Pharmaceuticals Inc (PCSA) has a Forward Free Cash Flow (FCF) yield of approximately -161.66%. Compared to its 3-year average FCF yield of -203.09%, the current FCF yield is approximately -20.40% lower. Relative to its 5-year average FCF yield of -125.80%, the current FCF yield is about 28.51% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for PCSA competitors is 21.93, providing a benchmark for relative valuation. Processa Pharmaceuticals Inc Corp (PCSA.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of PCSA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of PCSA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is PCSA currently overvalued or undervalued?

What is Processa Pharmaceuticals Inc (PCSA) fair value?

PCSA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Processa Pharmaceuticals Inc (PCSA) is between to according to relative valuation method.

How does PCSA's valuation metrics compare to the industry average?

The average P/S ratio for PCSA's competitors is 21.93, providing a benchmark for relative valuation. Processa Pharmaceuticals Inc Corp (PCSA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Processa Pharmaceuticals Inc (PCSA) as of Mar 03 2026?

As of Mar 03 2026, Processa Pharmaceuticals Inc (PCSA) has a P/B ratio of 1.06. This indicates that the market values PCSA at 1.06 times its book value.

What is the current FCF Yield for Processa Pharmaceuticals Inc (PCSA) as of Mar 03 2026?

As of Mar 03 2026, Processa Pharmaceuticals Inc (PCSA) has a FCF Yield of -161.66%. This means that for every dollar of Processa Pharmaceuticals Inc's market capitalization, the company generates -161.66 cents in free cash flow.

What is the current Forward P/E ratio for Processa Pharmaceuticals Inc (PCSA) as of Mar 03 2026?

As of Mar 03 2026, Processa Pharmaceuticals Inc (PCSA) has a Forward P/E ratio of -0.47. This means the market is willing to pay $-0.47 for every dollar of Processa Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Processa Pharmaceuticals Inc (PCSA) as of Mar 03 2026?

As of Mar 03 2026, Processa Pharmaceuticals Inc (PCSA) has a Forward P/S ratio of 0.00. This means the market is valuing PCSA at $0.00 for every dollar of expected revenue over the next 12 months.

PCSA Valuation